Comorbidities and Coinfections in Latent TB
NCT04642755 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 300
Last updated 2023-11-22
Summary
Approximately 2 billion people worldwide are infected with Mycobacterium tuberculosis (TB), with 90% of individuals having latent infection (LTBI). The control of TB requires clearly delineated helper T cell (Th) 1 responses and, to a lesser extent, Th17 responses, which both play important roles in the induction and maintenance of protective immune responses in mouse models of TB infection and in the prevention of active disease, as seen in LTBI. During latency, M. tuberculosis is contained in localized granulomas. Mycobacteria specific T cells mediate delayed type hypersensitivity reactions to purified protein derivative (PPD), and this reaction is generally considered to indicate an LTBI status in the absence of demonstrable active infection.
Among the various risk factors that are known to play a role in promoting active TB, HIV is the most well studied and described. However, in low-HIV-endemic countries like India, other risk factors might play a more prominent role in active TB pathogenesis. These include malnutrition, diabetes mellitus (DM), and helminth infections. LTBI individuals with these comorbidities or coinfections could be at a higher risk for developing active TB than their "healthy" LTBI counterparts without these comorbidities. Thus, it is imperative to study the pathogenesis of TB infection and disease in these "at risk" populations.
In this study, we will estimate the prevalence of severe to moderate malnutrition, uncontrolled DM, and helminth infections in LTBI-positive individuals. We will collect samples from a cohort of individuals with LTBI, those with LTBI and coexistent malnutrition, DM, or helminth coinfection, and those without any of these conditions. Individual participation may last up to 6 months. The main objective of the study is to estimate the prevalence of malnutrition, DM, and helminth infections in LTBI individuals.
Simultaneously, we will perform transcriptomic, proteomic, and metabolomic assays, including profiles in serum and urine, to determine the biosignature portfolio of these individuals. In addition, immunological assays examining cytokine/chemokine signatures as well as other immune parameters related to innate and adaptive responses will be performed to enhance the understanding of the immunological cross talk between LTBI and malnutrition, DM, and helminth infections.
Conditions
- Latent Tuberculosis
- Diabete Mellitus
- Malnutrition
- Helminth Infection
Sponsors & Collaborators
-
National Institutes of Health (NIH)
collaborator NIH -
Tuberculosis Research Centre, India
lead OTHER_GOV
Principal Investigators
-
Subash Babu, MBBS, PhD · National Institute for Research in Tuberculosis
-
Thomas B Nutman, MD · National Institutes of Health (NIH)
Eligibility
- Min Age
- 14 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-04-19
- Primary Completion
- 2026-03-31
- Completion
- 2026-03-31
Countries
- India
Study Locations
More Related Trials
-
The Impact of Malnutrition on Immune Responses to Tuberculosis
NCT05044910 ·Status: ACTIVE_NOT_RECRUITING
-
Immunological Biomarkers in Tuberculosis Management
NCT04271397 ·Status: RECRUITING ·Phase: NA
-
Iron Absorption and Utilization During Tuberculosis and After Treatment
NCT02176772 ·Status: COMPLETED
-
Patients With Tuberculosis, Mycobacteriosis or Latent Tuberculosis
NCT06764576 ·Status: RECRUITING
-
Potential Role of Microbiome in Tuberculosis
NCT04985994 ·Status: COMPLETED
-
Lung Innate Immunity and Microbiome After Tuberculosis Exposure
NCT06526689 ·Status: RECRUITING
-
Effect of SARS-CoV-2 Disease on Immune Responses, Disease Severity and Treatment Outcomes in Pulmonary Tuberculosis
NCT04930978 ·Status: RECRUITING
-
The Effect of Parasitic Worm Infections on the Immune Response to Tuberculosis Bacteria
NCT00342017 ·Status: COMPLETED
-
Immune Responses to Mycobacterium Tuberculosis
NCT00340990 ·Status: COMPLETED
-
Evaluation of Immune Cell Markers in Diagnosis of Tuberculosis
NCT04148053 ·Status: UNKNOWN
-
Evaluation of a Novel Microbiological Diagnostic Test for Latent Mycobacterium Tuberculosis Infection
NCT06728930 ·Status: ENROLLING_BY_INVITATION
-
Blood Tuberculosis DNA Levels to Monitor Tuberculosis Treatment
NCT06845618 ·Status: RECRUITING
-
Diagnostic Utility of Mycobacterium Tuberculosis Cell-free DNA
NCT06439810 ·Status: RECRUITING
-
Immunocompetent Versus Immunocompromised Tuberculosis (TB) Patients
NCT06709157 ·Status: NOT_YET_RECRUITING
-
Tuberculosis in China
NCT01071603 ·Status: COMPLETED
-
Impact of LTBI Treatment on Glucose Tolerance and Chronic Inflammation
NCT04830462 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy, Security, Adherence, Tolerability and Cost Effectiveness of Latent TB Treatment in Patients With TB/DM2 (TBL)
NCT03278483 ·Status: COMPLETED ·Phase: PHASE4
-
The Role of a Mycobacterium Growth Inhibition Assay to Quantify Host Immune Control of M. Tuberculosis
NCT06580639 ·Status: RECRUITING
-
Tuberculosis - Learning the Effect of Parasites and Reinforcing Diets
NCT05048485 ·Status: COMPLETED
-
Expression of Tuberculosis in the Lung
NCT00201253 ·Status: COMPLETED
-
Diagnosis of Active and Latent TB Infection With IFN-y Assays in African Children
NCT00456469 ·Status: UNKNOWN
-
Immunogenicity of COVID-19 Vaccines in Tuberculosis Patients
NCT05571735 ·Status: RECRUITING
-
Efficacy and Safety of Immunomodulator as an Adjunct Therapy in New Pulmonary Tuberculosis(Category I) Patients.
NCT00341328 ·Status: COMPLETED ·Phase: PHASE3
-
Cytometric Immunodiagnostics of Latent Tuberculosis Infection (LTBI)
NCT04673227 ·Status: UNKNOWN
-
Clinical Analysis of Safety in Latent Tuberculosis Infection Prophylaxis Treatment
NCT04655794 ·Status: UNKNOWN